Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors [PDF]
EJNMMI Research, 2020 Purpose Targeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-particle emitter ...
Tom A. Bäck +11 more
doaj +2 more sources
In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211 [PDF]
EJNMMI Radiopharmacy and ChemistryBackground A significant challenge in cancer therapy lies in eradicating hidden disseminated tumor cells. Within Nuclear Medicine, Targeted Alpha Therapy is a promising approach for cancer treatment tackling disseminated cancer.
Chiara Timperanza +5 more
doaj +2 more sources
Evolution of production of Astatine-211 in Orléans Cyclotron [PDF]
, 2015 Introduction Since 2005, we produce, at academic scale in Orleans, 211At for needs of chemistry and physicians teams of Nantes in research project of alpha immunotherapy.
Da Silva, I. +5 more
core +5 more sources
Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer. [PDF]
Nucl Med Biol, 2021 Li Y +5 more
europepmc +3 more sources
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology. [PDF]
Eur J Nucl Med Mol Imaging, 2023 Chakravarty R +3 more
europepmc +3 more sources
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease. [PDF]
Cancers (Basel), 2020 Gouard S +12 more
europepmc +3 more sources
Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics [PDF]
MoleculesThe prostate-specific membrane antigen (PSMA) is a well-established target for radiotheranostics in prostate cancer. We previously demonstrated that 4-(p-astatophenyl)butyric acid (APBA), an albumin-binding moiety (ABM) labeled with astatine-211 (211At),
Saki Hirata +9 more
doaj +2 more sources
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project [PDF]
PharmaceuticalsThis review comprehensively assesses the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment.
Valentina Di Iorio +14 more
doaj +2 more sources
Production of 211At and automated radiosynthesis of [211At]MABG via electrophilic astatodesilylation [PDF]
EJNMMI Radiopharmacy and ChemistryBackground [211At]m-Astatobenzylguanidine ([211At]MABG) has demonstrated potent antitumor efficacy in preclinical models of malignant neuroendocrine tumours including neuroblastoma and pheochromocytoma/paraganglioma.
Yuto Kondo +11 more
doaj +2 more sources